drugset
drugset / Trial / NCT03936153

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT03936153 ↗

Phase 2 Recruiting 170 enrolled Xynomic Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Timeline

Start
2020-01-20
Primary completion
2026-07-31
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Abexinostat Small molecule 80 mg Oral

Indications

diffuse large B-cell lymphoma